Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Summary

The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.

Timeline

Start

2003-11

Primary completion

2006-04

Completion

—

Outcome

Met primary endpoint

paper The primary endpoint was superior in Group 1 (24%) and statistically noninferior in Group 2 compared to Group 3 PMID 17984842 ↗

paper compared to Group 3 (24.1% vs. 29.2% vs. 39.4%; P=0.025 and 0.0039, respectively). PMID 17984842 ↗

Publications

• Results Tedesco-Silva H, Szakaly P, Shoker A, Sommerer C, Yoshimura N, Schena FP, Cremer M, Hmissi A, Mayer H, Lang P; FTY720 2218 Clinical Study Group. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation. 2007 Oct 15;84(7):885-92. doi: 10.1097/01.tp.0000281385.26500.3b.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fingolimod	Small molecule	2.5 mg	—
Subject	Fingolimod	Small molecule	5 mg	—

Indications

No indication recorded.